Nevertheless, IL-13 and IL-17 inhibition protected the animals from eosinophilia, mucus hyperplasia, and hyperresponsiveness of the airways and the elimination of neutrophilic inflammation, suggesting the effectiveness of combination therapies that control both Th2 and Th17 responses (46). This evidence concerns the gene IL13 and Increased total eosinophil count.